{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024717","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.579695+00:00","generated_at":"2026-06-13T07:42:19.265586+00:00","sec_items":["3.03","5.03","4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Evofem Biosciences dismisses Deloitte, appoints BPM as auditor; reduces stockholder quorum to one-third","bullets":["Dismissed Deloitte & Touche as auditor effective July 11, 2023; no disagreements but prior reports included going-concern qualification.","Appointed BPM LLP as new independent auditor, subject to stockholder ratification at 2023 Annual Meeting.","Previously disclosed material weaknesses in internal control over financial reporting as of Dec 31, 2022.","Amended bylaws to reduce quorum requirement for stockholder meetings from majority to one-third of outstanding shares.","Removed requirement for Board consent to reschedule annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024717","json":"https://secwatch.observer/filing/0001493152-23-024717.json","markdown":"https://secwatch.observer/filing/0001493152-23-024717.md","text":"https://secwatch.observer/filing/0001493152-23-024717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223024717/0001493152-23-024717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223024717/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:42:19.265586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ae4d75d6180c7077cda9a061907bbc6c0a2b29e","claim":"Evofem Biosciences, Inc. dismissed Deloitte & Touche LLP as its auditor.","evidence_excerpt":"the Audit Committee recommended, and the Board approved the dismissal of Deloitte & Touche LLP (\"Deloitte\"), as the Company's independent registered public accounting firm, on July 11, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223024717/0001493152-23-024717-index.htm","confidence":0.96,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Deloitte & Touche LLP"},{"label":"Successor","value":"BPM LLP"}],"fact_type":"auditor_change"},{"claim_id":"b2006d40cd233fe34697552d2b1151f034e612fc","claim":"Evofem Biosciences, Inc. engaged BPM LLP as its auditor.","evidence_excerpt":"On July 11, 2023, the Company appointed BPM LLP (\"BPM\") as the Company's new independent registered public accounting firm effective as of July 11, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223024717/0001493152-23-024717-index.htm","confidence":0.97,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"BPM LLP"}],"fact_type":"auditor_change"},{"claim_id":"beb8696044af3ab174156b80c26cfc7ed533deb2","claim":"Evofem Biosciences, Inc.: Amended and restated bylaws to remove requirement for Board consent to reschedule annual meeting and reduce quorum from a majority to one-third (effective 2023-07-11).","evidence_excerpt":"On July 11, 2023, the board of directors the (“Board”) of Evofem Biosciences, Inc. (the “Company”), adopted and approved an amendment and restatement of the Company’s Amended and Restated Bylaws (the “Second Amended and Restated Bylaws”) in order to change, among other things: ● Section 2, removing requirement for Board Consent to reschedule annual meeting ● Section 3, so the proportion of shares present required to constitute a quorum at a meeting of stockholders, from a majority to one-third of the outstanding shares of stock entitled to vote, as permitted under § 216 of the Delaware General Corporation Law.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223024717/0001493152-23-024717-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-07-11"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}